Press Releases

Entasis Therapeutics to Present at H.C. Wainwright & Co. Global Life Sciences Conference in London

April 2, 2019 at 8:00 AM EDT

WALTHAM, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer, will present at the H.C, Wainwright & Co.Global Life Sciences Conference being held April 7-9, 2019 in London, UK.

Details of the presentation are below:
Event: H.C. Wainwright & Co.Global Life Sciences Conference
Date: Tuesday, April 9, 2019
Time: 11:10 AM GMT / 7:10 AM EDT

In addition to his presentation, Dr. Perros will be hosting 1-on-1 investor meetings at the conference. Investors attending the conference who are interested in meeting with Entasis management should contact their H.C. Wainwright representatives.

About Entasis
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ targeted-design platform has produced a pipeline of product candidates, including ETX2514SUL (targeting A. baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). For more information, visit

Entasis Company Contact             
Kyle Dow
Entasis Therapeutics
(781) 810-0114

Investor Relations Contact
Lee Roth
The Ruth Group
(646) 536-7012

Media Contact
Kirsten Thomas
The Ruth Group
(508) 280-6592

Source: Entasis Therapeutics Holdings Inc.